GLP-1 use linked to lower breast cancer incidence in large cohort study
medicalxpress - A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30% less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presente…
AI Summary: A large observational cohort study reported an association between GLP‑1 agonist use and a lower incidence of breast cancer. The result is intriguing and may spur biological investigation, but researchers caution against causal claims—confounding and indication bias mean randomized trials would be required to confirm any protective effect.
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma
esmo - Findings from the HERIZON-GEA-01 study
AI Summary: A phase 3 readout from the HERIZON‑GEA‑01 program shows zanidatamab plus chemotherapy prolongs progression‑free survival compared with trastuzumab plus chemotherapy in HER2‑positive advanced gastro‑oesophageal adenocarcinoma. The data, now published and debated at ASCO, also probes whether adding anti‑PD‑1 therapy (tislelizumab) meaningfully changes outcomes — promising for a tough cancer, if you like incremental revolutions.
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke / nature - Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-xAs presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAG…
AI Summary: A phase 1 trial of a TCR‑based bispecific T‑cell engager targeting MAGE‑A4 and MAGE‑A8 demonstrated early anti‑tumor activity in recurrent or refractory solid tumors, with an acceptable safety profile in dose‑finding cohorts. These results revive interest in targeting intracellular cancer antigens via T‑cell redirection, nudging immunotherapy beyond familiar checkpoint territory.
RASolute 302 Trial at ASCO 2026 Plennary Session: Daraxonrasib Improves Survival Versus Chemotherapy in Previously Treated Metastatic PDAC
oncodaily - RASolute 302 Trial was presented by Brian M. Wolpin, MD, MPH, during the 2026 ASCO Annual Meeting.The Trial evaluated daraxonrasib, an oral RAS(ON) multi-selective inhibitor, against investigator’s choice chemotherapy in […]
AI Summary: A plenary ASCO presentation reports daraxonrasib, an oral KRAS G12C inhibitor, significantly improved overall survival compared with chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. The data prompted immediate planning across cancer centers for anticipated demand and access changes — a rare dose of good news for a disease that usually gets none.
OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
MajesTEC-9 Results at ASCO 2026: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
oncodaily - At ASCO 2026, results from MajesTEC-9 (NCT05572515), the first phase 3 study of teclistamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, […]
AI Summary: Teclistamab monotherapy demonstrated superior progression-free survival and response rates versus pomalidomide‑based (PVd) and carfilzomib‑based (Kd) regimens in earlier-line relapsed/refractory multiple myeloma, showing durable remissions at 18 months. The data suggest a shift toward bispecific antibody therapy earlier in the treatment sequence for many patients.
- ASCO social media: expert reactions and highlights (4)
- MajesTEC‑9: Teclistamab outperforms PVd/Kd (4)
- Other BCMA and novel myeloma immunotherapies at ASCO (3)
- All Other Stories
ASCO social media: expert reactions and highlights
MajesTEC‑9: Teclistamab outperforms PVd/Kd
Other BCMA and novel myeloma immunotherapies at ASCO
All Other Stories
FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN
oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]
AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.
- ASCO 2026: ADC education, efficacy signals, and ocular toxicity (4)
- Decnupaz approval reshapes BPDCN treatment landscape (4)
- Real-world ADC safety: infection risks and rechallenge questions (3)
ASCO 2026: ADC education, efficacy signals, and ocular toxicity
Decnupaz approval reshapes BPDCN treatment landscape
Real-world ADC safety: infection risks and rechallenge questions
Simple blood test could lead to personalized lung cancer treatment
medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…
AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.
- Blood tests for monitoring and personalizing lung cancer care (4)
- MCED trials and clinical benefit debate (4)
- Methylation liquid biopsy methods and applications (4)
- All Other Stories
Blood tests for monitoring and personalizing lung cancer care
MCED trials and clinical benefit debate
Methylation liquid biopsy methods and applications
All Other Stories
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...
AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.
- Clinicians weigh Datroway’s role in TNBC care (3)
- FDA win and market stakes for Datroway (3)
- All Other Stories
Clinicians weigh Datroway’s role in TNBC care
FDA win and market stakes for Datroway
All Other Stories
Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…
AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.
Skin cancer cases hit record high in the UK
Sydney Ghazarian / cancerresearchuk - New analysis shows that melanoma skin cancer rates in the UK have reached a new high of 20,000 cases per yearThe post Skin cancer cases hit record high in the UK appeared first on Cancer Research UK - Cancer News.
AI Summary: The UK has recorded its highest-ever number of skin cancer cases, with an alarming rise in the most dangerous presentations. Public health experts point to changing sun behaviours and inadequate sun protection as likely contributors. The surge signals strain on dermatology services and a need for clearer messaging—because sunscreen confusion apparently remains a public health hobby.
Common asthma drug helps fight hard-to-treat cancers, including aggressive breast cancers, early study finds
livescience - Scientists found that blocking a protein best known for its role in asthma enhances cancer immunotherapy in preclinical models.
AI Summary: Early studies report that a widely used asthma medication can switch off a tumor immune‑evasion pathway and restore anti‑tumor immunity in models and early human data, improving responses in some hard‑to‑treat cancers including aggressive breast tumours. Researchers call for larger trials to confirm clinical benefit and safety.
- Asthma drug revives anti‑tumor immunity in resistant cancers (5)
- Mechanisms and meetings on immunotherapy resistance (5)
- All Other Stories
Asthma drug revives anti‑tumor immunity in resistant cancers
Mechanisms and meetings on immunotherapy resistance
All Other Stories
Toronto Rock take NLL Cup with win over Halifax Thunderbirds
Denio Lourenco / citynews - Owen Hiltz and Chris Boushy each had three goals and an assist, Mark Matthews had a goal and three assists, and Nick Rose made 34 saves as the Toronto Rock defeated the Halifax Thunderbirds 12-7 to win the National Lacrosse League championship on Sunday a…
AI Summary: A clinical study shows that delivering just two ablative radiotherapy sessions over eight days achieves effective control of localized prostate cancer without adding side effects, offering a dramatically shorter, patient‑friendly regimen. If adopted more widely, the approach could reduce treatment burden, clinic visits and health‑system costs while maintaining cancer control.
Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line Treatment of Patients with Advanced Squamous Anal Cancer
esmo - Findings from the final overall survival analysis in the POD1UM-303/InterAACT-2 study
AI Summary: A randomized first‑line trial found that adding retifanlimab to standard chemotherapy meaningfully improved overall survival for patients with advanced squamous anal cancer, signaling a new immunotherapy-containing option where few exist. The data from the POD1UM‑303/InterAACT‑2 program offer clinicians a viable strategy to extend life without reinventing the wheel.
OLIGOMA Trial: SBRT Extends PFS in Oligometastatic Breast Cancer
oncodaily - The OLIGOMA trial presented at ESTRO 2026 brings new attention to one of the most debated questions in metastatic breast cancer: can treating limited metastatic sites with stereotactic body radiotherapy […]
AI Summary: A randomized trial shows stereotactic body radiotherapy (SBRT) targeting limited metastatic breast lesions prolongs progression‑free survival, offering longer disease control for selected patients with oligometastatic disease. Toxicity was manageable, suggesting SBRT could become a pragmatic, tissue‑sparing option to delay systemic therapy escalation.
- ESTRO reaction: clinicians and advocates amplify SBRT findings (3)
- EXTEND and practice: metastasis-directed therapy, guidelines, and AI (4)
- OLIGOMA: SBRT extends PFS in oligometastatic breast cancer (3)
- All Other Stories
ESTRO reaction: clinicians and advocates amplify SBRT findings
EXTEND and practice: metastasis-directed therapy, guidelines, and AI
OLIGOMA: SBRT extends PFS in oligometastatic breast cancer
All Other Stories
Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds
medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.
- MYC hijacks DNA repair to enable chemo resistance (4)
- Other molecular drivers of chemoresistance and genome instability (3)
- Tumor cell death and immunity shape chemotherapy outcomes (3)
- All Other Stories